Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

Biogen said the U.S. Food and Drug Administration has accepted its supplemental new-drug application, while the European Medicines Agency has validated its application, which confirms that the ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...